The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.
Institute of Molecular Medicine, Tumor Biology Center, Freiburg, Germany.
G
G
Siemeister
G
G
Martiny-Baron
D
D
Marmé
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016228:Endothelial Growth Factors / Q000502:physiology*; D006801:Humans; D008222:Lymphokines / Q000502:physiology*; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000503:physiopathology; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology*; D040262:Receptors, Vascular Endothelial Growth Factor; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D017978:Receptors, Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor